Merck KGaA, a leading science and technology company, met its targets for 2017 and achieved important strategic successes with the approvals of two new medicines.
Sales increased over the previous year whereas EBITDA pre (earnings before interest, taxes, depreciation and amortization), which was adversely impacted by negative foreign exchange effects, declined slightly. In 2017, Merck generated net sales of €15.3 billion. This increase of 2.0% over the previous year (€15.0 billion) was mainly attributable to the strong organic sales performance of the Healthcare and Life Science business sectors.
The operating result (EBIT) rose by 1.8% to €2.5 billion (2016: €2.5 billion). EBITDA pre, the company’s most important earnings figure, declined by -1.7% to € 4.4 billion. Net income rose in 2017 by nearly 60% to a record level of € 2.6 billion. The company thus succeeded in meeting all targets in a challenging market environment.
“2017 was a good year for Merck. We performed well in a challenging environment and met all our targets for the year,” said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck. “We are staying the course and will continue to purposefully implement our innovation-driven growth strategies for Healthcare, Life Science and Performance Materials,” Oschmann stated further.